Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma

The Chinese traditional medicine KangXianYiAi formula (KXYA) is used to treat hepatic disease in the clinic. Here we aim to confirm the therapeutic effects and explore the pharmacological mechanisms of KXYA on hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). We first collected and analyzed clinical data of 40 chronic hepatitis B (CHB) patients with precancerous liver lesions under KXYA treatment. Then, the cell viability, migration, cell cycle, and apoptosis of HepAD38 cells with KXYA treatment were examined. Next, we performed network pharmacological analysis based on database mining to obtain the key target pathways and genes of KXYA treatment on HBV-related HCC. We finally analyzed the expression of the key genes between normal and HBV-related HCC tissues in databases and measured the mRNA expression of the key genes in HepAD38 cells after KXYA treatment. The KXYA treatment could reduce the liver nodule size of CHB patients, suppress the proliferation and migration capabilities, and promote apoptosis of HepAD38 cells. The key pathways of KXYA on HBV-related HCC were Cancer, Hepatitis B, Viral carcinogenesis, Focal adhesion, and PI3K-Akt signaling, and KXYA treatment could regulate the expression of the key genes including HNF4A, MAPK8, NR3C1, PTEN, EGFR, and HDAC1. The KXYA exhibited a curative effect via inhibiting proliferation, migration, and promoting apoptosis of HBV-related HCC and the pharmacological mechanism was related to the regulation of the expression of HNF4A, MAPK8, NR3C1, PTEN, EGFR, and HDAC1.

[1]  N. Pochet,et al.  Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation , 2022, JCI insight.

[2]  G. Tiao,et al.  HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer , 2021, Cellular and molecular gastroenterology and hepatology.

[3]  Y. Ye,et al.  The mechanism of TiaoGanYiPi formula for treating chronic hepatitis B by network pharmacology and molecular docking verification , 2021, Scientific Reports.

[4]  Jun Li,et al.  New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage , 2021, World journal of gastroenterology.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  Liyun He,et al.  Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial , 2020, Hepatology International.

[7]  Navid Rabiee,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[8]  Luming Liu,et al.  Integrated Analyses Identify Immune-Related Signature Associated with Qingyihuaji Formula for Treatment of Pancreatic Ductal Adenocarcinoma Using Network Pharmacology and Weighted Gene Co-Expression Network , 2020, Journal of immunology research.

[9]  A. Siddiqui,et al.  HBV‐Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC , 2020, Hepatology.

[10]  Jing Li,et al.  HNF-4α inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway , 2020, PloS one.

[11]  Le Wang,et al.  A systematic analysis of natural α-glucosidase inhibitors from flavonoids of Radix scutellariae using ultrafiltration UPLC-TripleTOF-MS/MS and network pharmacology , 2020, BMC Complementary Medicine and Therapies.

[12]  F. Sanz,et al.  The DisGeNET knowledge platform for disease genomics: 2019 update , 2019, Nucleic Acids Res..

[13]  Guohua Yu,et al.  Uncovering the pharmacological mechanism of Carthamus tinctorius L. on cardiovascular disease by a systems pharmacology approach. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  Olivier Michielin,et al.  SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules , 2019, Nucleic Acids Res..

[15]  Hannah M. Lee,et al.  Updates on Chronic HBV: Current Challenges and Future Goals , 2019, Current Treatment Options in Gastroenterology.

[16]  A. Pillai,et al.  Goals and targets for personalized therapy for HCC , 2019, Hepatology International.

[17]  B. Győrffy,et al.  Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma , 2018, Royal Society Open Science.

[18]  G. Minuk,et al.  Role of traditional Chinese medicine in the management of patients with hepatocellular carcinoma , 2018, World journal of hepatology.

[19]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[20]  Junnian Zheng,et al.  JNK1/2 and ERK1/2 provides vital clues about tumor recurrence and survival in hepatocellular carcinoma patients. , 2018, Future oncology.

[21]  Li Hu,et al.  [Development and research advance of pharmacognosy field based on CNKI]. , 2018, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

[22]  U. Garaigorta,et al.  Hepatitis B Virus and DNA Damage Response: Interactions and Consequences for the Infection , 2017, Viruses.

[23]  D. Sinn,et al.  Low‐level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment , 2017, Hepatology.

[24]  Y. Maehara,et al.  Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma. , 2017, Human pathology.

[25]  Yongfang Jiang,et al.  HBx promotes cell proliferation by disturbing the cross-talk between miR-181a and PTEN , 2017, Scientific Reports.

[26]  Junwei Hou,et al.  Hepatitis B virus mRNAs functionally sequester let-7a and enhance hepatocellular carcinoma. , 2016, Cancer letters.

[27]  W. Cong,et al.  Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update , 2016, World journal of gastroenterology.

[28]  Kumaresan Ganesan,et al.  Integrative functional genomic delineation of the cascades of transcriptional changes involved in hepatocellular carcinoma progression , 2016, International journal of cancer.

[29]  Liang Li,et al.  Heterogeneity of liver cancer and personalized therapy. , 2016, Cancer letters.

[30]  Tsippi Iny Stein,et al.  The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses , 2016, Current protocols in bioinformatics.

[31]  M. Yuen,et al.  Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region , 2016, Gut and liver.

[32]  B. Hu,et al.  Inhibitory effects of shRNA on expression of JNK1 and migration and invasion in mouse hepatocellular carcinoma cell lines mediated by ultrasound-targeted microbubble destruction. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[33]  Damian Szklarczyk,et al.  STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data , 2015, Nucleic Acids Res..

[34]  Gang Fu,et al.  PubChem Substance and Compound databases , 2015, Nucleic Acids Res..

[35]  Stephen S. Taylor,et al.  Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy , 2015, Proceedings of the National Academy of Sciences.

[36]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[37]  Meng Li,et al.  Hepatitis B Virus X Protein Stabilizes Cyclin D1 and Increases Cyclin D1 Nuclear Accumulation through ERK-Mediated Inactivation of GSK-3β , 2015, Cancer Prevention Research.

[38]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[39]  François Schiettecatte,et al.  OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders , 2014, Nucleic Acids Res..

[40]  D. Pan,et al.  Decreased Expression of Hepatocyte Nuclear Factor 4α (Hnf4α)/MicroRNA-122 (miR-122) Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Protein Activity* , 2014, The Journal of Biological Chemistry.

[41]  Tatiana A. Tatusova,et al.  Gene: a gene-centered information resource at NCBI , 2014, Nucleic Acids Res..

[42]  A. Barabasi,et al.  Human symptoms–disease network , 2014, Nature Communications.

[43]  S. Imbeaud,et al.  Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas , 2014, Gut.

[44]  Meng Li,et al.  The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. , 2014, Journal of hepatology.

[45]  Wei Zhou,et al.  TCMSP: a database of systems pharmacology for drug discovery from herbal medicines , 2014, Journal of Cheminformatics.

[46]  Yanqiong Zhang,et al.  A systems biology-based investigation into the therapeutic effects of Gansui Banxia Tang on reversing the imbalanced network of hepatocellular carcinoma , 2014, Scientific Reports.

[47]  S. Kumano,et al.  Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. , 2013, Radiology.

[48]  Gary D Bader,et al.  A travel guide to Cytoscape plugins , 2012, Nature Methods.

[49]  Young Kon Kim,et al.  Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. , 2012, Radiology.

[50]  U. Motosugi,et al.  Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease , 2011, Journal of magnetic resonance imaging : JMRI.

[51]  M. Buendia,et al.  Mechanisms of HBV-related hepatocarcinogenesis. , 2010, Journal of hepatology.

[52]  Wanling Yang,et al.  Linked region detection using high-density SNP genotype data via the minimum recombinant model of pedigree haplotype inference , 2009, BMC Bioinformatics.

[53]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[54]  K. Vermeulen,et al.  Cell cycle and apoptosis , 2003, Cell proliferation.

[55]  M. Otto,et al.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication , 1997, Antimicrobial agents and chemotherapy.

[56]  I. Wanless,et al.  Terminology of nodular hepatocellular lesions , 1995 .

[57]  F. Hu,et al.  Cell Culture Models and Animal Models for HBV Study. , 2020, Advances in experimental medicine and biology.

[58]  Yangyang Fu,et al.  Molecular Carcinogenesis , 2019 .

[59]  Michael Kohl,et al.  Cytoscape: software for visualization and analysis of biological networks. , 2011, Methods in molecular biology.

[60]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.